Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.

Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo PE, Bleuse JP, Kramar A, Romieu G.

Am J Clin Oncol. 2010 Dec;33(6):544-9. doi: 10.1097/COC.0b013e3181bead47.

PMID:
20042972
2.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
3.
4.

Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.

Nieto Y, Aramendía JM, Espinós J, De la Cruz S, Fernández-Hidalgo O, Santisteban M, Arbea L, Aristu J, Martínez-Monge R, Moreno M, Pina L, Sola J, Zornoza G, Regueira FM.

Cancer Chemother Pharmacol. 2010 Feb;65(3):457-65. doi: 10.1007/s00280-009-1049-y. Epub 2009 Jun 14.

PMID:
19526361
5.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A.

J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3.

PMID:
23733779
6.

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.

Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group.

Breast Cancer. 2005;12(2):99-103.

7.

Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.

Amat S, Mouret-Reynier MA, Penault-Llorca F, Leheurteur M, Delva R, Coudert B, Leduc B, Dauplat J, Curé H, Chollet P.

Clin Breast Cancer. 2006 Aug;7(3):262-9.

PMID:
16942644
8.

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.

Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CL.

Breast Cancer Res Treat. 2005 Sep;93(1):67-74.

PMID:
16184461
9.

Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.

Burdette-Radoux S, Wood ME, Olin JJ, Laughlin RS, Crocker AM, Ashikaga T, Muss HB.

Breast J. 2007 May-Jun;13(3):274-80.

PMID:
17461902
10.

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.

Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S.

Expert Opin Investig Drugs. 2013 Mar;22(3):299-307. doi: 10.1517/13543784.2013.766715.

PMID:
23394482
11.

A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.

Antolín S, Mel R, Ramos M, García-Palomo A, Almanza C, de Paz L, Calvo L, Alvarez E, González A, García-Mata J.

Clin Transl Oncol. 2011 Sep;13(9):686-91. doi: 10.1007/s12094-011-0715-9.

PMID:
21865141
12.

Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).

Sakr H, Hamed RH, Anter AH, Yossef T.

Med Oncol. 2013 Mar;30(1):457. doi: 10.1007/s12032-013-0457-3. Epub 2013 Jan 16.

PMID:
23322524
13.
14.

Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.

Clin Breast Cancer. 2002 Dec;3(5):333-40.

PMID:
12533263
15.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group.

Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18.

16.

Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.

Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ.

Am J Clin Oncol. 2010 Dec;33(6):624-8. doi: 10.1097/COC.0b013e3181bead92.

PMID:
20142726
17.

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

Sanna G, Pestrin M, Zafarana E, Biagioni C, Cavaciocchi D, Turner N, Di Leo A, Biganzoli L.

Breast. 2013 Oct;22(5):926-32. doi: 10.1016/j.breast.2013.04.019. Epub 2013 May 22.

PMID:
23707082
18.

[Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].

Cortés-Flores AO, Morgan-Villela G, Castro-Cervantes JM, Vázquez-Camacho G, Fuentes-Orozco C, González-Ojeda A.

Cir Cir. 2008 Jan-Feb;76(1):23-8. Spanish.

PMID:
18492416
19.

Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H.

J Clin Oncol. 2012 Jan 1;30(1):11-8. doi: 10.1200/JCO.2011.35.4639. Epub 2011 Nov 21.

PMID:
22105826
20.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.

PMID:
21684812

Supplemental Content

Support Center